Marshall Fordyce's Insider Trades & SAST Disclosures
Marshall Fordyce's most recent trade in Vera Therapeutics Inc - Ordinary Shares - Class A was a trade of 10,613 Class A Common Stock done at an average price of $27.9 . Disclosure was reported to the exchange on Feb. 21, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Marshall Fordyce.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 27.89 per share. | 21 Feb 2025 | 10,613 | 213,740 | - | 27.9 | 296,032 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 27.55 per share. | 21 Feb 2025 | 7,975 | 205,765 | - | 27.6 | 219,732 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 28.32 per share. | 21 Feb 2025 | 1,100 | 204,665 | - | 28.3 | 31,150 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 161,500 | 161,500 | - | - | Stock Option (right to buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 80,750 | 224,353 | - | 0 | Class A Common Stock | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 57,661 | 626,551 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 18 Dec 2024 | 57,661 | 143,603 | - | 2.9 | 167,032 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 15,625 | 686,087 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 18 Dec 2024 | 5,023 | 90,965 | - | 2.9 | 14,551 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 43.52 per share. | 18 Dec 2024 | 5,023 | 85,942 | - | 43.5 | 218,609 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 44.03 per share. | 18 Dec 2024 | 4,635 | 85,942 | - | 44.0 | 204,094 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 18 Dec 2024 | 4,635 | 90,577 | - | 2.9 | 13,427 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 41.33 per share. | 18 Dec 2024 | 3,772 | 85,942 | - | 41.3 | 155,883 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 18 Dec 2024 | 3,772 | 89,714 | - | 2.9 | 10,927 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 42.35 per share. | 18 Dec 2024 | 2,195 | 85,942 | - | 42.3 | 92,949 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 18 Dec 2024 | 2,195 | 88,137 | - | 2.9 | 6,358 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 1,875 | 684,212 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 18 Dec 2024 | 1,875 | 87,817 | - | 2.9 | 5,432 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 43.81 per share. | 18 Dec 2024 | 1,875 | 85,942 | - | 43.8 | 82,144 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2024 | 15,625 | 703,587 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 46.91 per share. | 11 Dec 2024 | 14,925 | 85,942 | - | 46.9 | 700,150 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 11 Dec 2024 | 14,925 | 100,867 | - | 2.9 | 43,235 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2024 | 1,875 | 701,712 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 11 Dec 2024 | 1,775 | 87,717 | - | 2.9 | 5,142 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 46.94 per share. | 11 Dec 2024 | 1,775 | 85,942 | - | 46.9 | 83,325 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 47.55 per share. | 11 Dec 2024 | 700 | 85,942 | - | 47.5 | 33,284 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 11 Dec 2024 | 700 | 86,642 | - | 2.9 | 2,028 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 47.65 per share. | 11 Dec 2024 | 100 | 85,942 | - | 47.7 | 4,765 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 11 Dec 2024 | 100 | 86,042 | - | 2.9 | 290 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 15,625 | 722,962 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 48.18 per share. | 25 Nov 2024 | 7,665 | 85,942 | - | 48.2 | 369,330 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Nov 2024 | 7,665 | 93,607 | - | 2.9 | 22,204 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 47.05 per share. | 25 Nov 2024 | 6,579 | 85,942 | - | 47.0 | 309,532 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Nov 2024 | 6,579 | 92,521 | - | 2.9 | 19,058 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.00 per share. | 25 Nov 2024 | 1,875 | 85,942 | - | 49 | 91,875 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 48.76 per share. | 25 Nov 2024 | 1,875 | 85,942 | - | 48.8 | 91,425 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Nov 2024 | 1,875 | 87,817 | - | 2.9 | 5,432 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 1,875 | 721,087 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 1,875 | 719,212 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Nov 2024 | 1,875 | 87,817 | - | 2.9 | 5,432 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Nov 2024 | 1,381 | 87,323 | - | 2.9 | 4,000 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 48.80 per share. | 25 Nov 2024 | 1,381 | 85,942 | - | 48.8 | 67,399 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 15,625 | 753,587 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 12,218 | 98,160 | - | 2.9 | 35,393 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.54 per share. | 13 Nov 2024 | 12,218 | 85,942 | - | 49.5 | 605,314 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 7,500 | 738,587 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.00 per share. | 13 Nov 2024 | 7,500 | 85,942 | - | 49 | 367,500 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 7,500 | 93,442 | - | 2.9 | 21,726 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 50.28 per share. | 13 Nov 2024 | 3,307 | 85,942 | - | 50.3 | 166,281 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 3,307 | 89,249 | - | 2.9 | 9,580 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 1,875 | 747,962 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 1,875 | 749,837 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 1,875 | 746,087 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 1,875 | 751,712 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.50 per share. | 13 Nov 2024 | 1,875 | 85,942 | - | 49.5 | 92,811 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 1,875 | 87,817 | - | 2.9 | 5,432 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.52 per share. | 13 Nov 2024 | 1,875 | 85,942 | - | 49.5 | 92,849 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 1,875 | 87,817 | - | 2.9 | 5,432 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.57 per share. | 13 Nov 2024 | 1,875 | 85,942 | - | 49.6 | 92,951 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 1,875 | 87,817 | - | 2.9 | 5,432 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.59 per share. | 13 Nov 2024 | 1,565 | 85,942 | - | 49.6 | 77,603 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 1,565 | 87,507 | - | 2.9 | 4,533 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 50.35 per share. | 13 Nov 2024 | 310 | 85,942 | - | 50.4 | 15,609 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 310 | 86,252 | - | 2.9 | 898 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 51.20 per share. | 13 Nov 2024 | 100 | 85,942 | - | 51.2 | 5,120 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 100 | 86,042 | - | 2.9 | 290 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Oct 2024 | 15,625 | 772,962 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 39.81 per share. | 23 Oct 2024 | 12,715 | 307,972 | - | 39.8 | 506,121 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 23 Oct 2024 | 12,715 | 320,687 | - | 2.9 | 36,833 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 42.00 per share. | 23 Oct 2024 | 3,750 | 307,972 | - | 42 | 157,500 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 23 Oct 2024 | 3,750 | 311,722 | - | 2.9 | 10,863 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 40.70 per share. | 23 Oct 2024 | 2,310 | 307,972 | - | 40.7 | 94,022 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 23 Oct 2024 | 2,310 | 310,282 | - | 2.9 | 6,692 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Oct 2024 | 1,875 | 769,212 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Oct 2024 | 1,875 | 771,087 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 41.61 per share. | 23 Oct 2024 | 600 | 307,972 | - | 41.6 | 24,968 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 23 Oct 2024 | 600 | 308,572 | - | 2.9 | 1,738 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2024 | 15,625 | 788,587 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 38.08 per share. | 09 Oct 2024 | 12,273 | 307,972 | - | 38.1 | 467,406 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 09 Oct 2024 | 12,273 | 320,245 | - | 2.9 | 35,552 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 09 Oct 2024 | 3,352 | 311,324 | - | 2.9 | 9,710 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 38.83 per share. | 09 Oct 2024 | 3,352 | 307,972 | - | 38.8 | 130,162 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2024 | 15,625 | 811,712 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 45.42 per share. | 25 Sep 2024 | 8,643 | 307,972 | - | 45.4 | 392,608 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Sep 2024 | 8,643 | 316,615 | - | 2.9 | 25,037 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 46.62 per share. | 25 Sep 2024 | 4,817 | 307,972 | - | 46.6 | 224,588 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Sep 2024 | 4,817 | 312,789 | - | 2.9 | 13,954 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 47.06 per share. | 25 Sep 2024 | 2,165 | 307,972 | - | 47.1 | 101,883 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Sep 2024 | 2,165 | 310,137 | - | 2.9 | 6,272 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2024 | 1,875 | 804,212 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2024 | 1,875 | 806,087 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2024 | 1,875 | 807,962 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2024 | 1,875 | 809,837 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 45.44 per share. | 25 Sep 2024 | 975 | 307,972 | - | 45.4 | 44,301 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Sep 2024 | 975 | 308,947 | - | 2.9 | 2,824 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 45.48 per share. | 25 Sep 2024 | 975 | 307,972 | - | 45.5 | 44,341 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Sep 2024 | 975 | 308,947 | - | 2.9 | 2,824 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 45.43 per share. | 25 Sep 2024 | 975 | 307,972 | - | 45.4 | 44,292 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Sep 2024 | 975 | 308,947 | - | 2.9 | 2,824 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 45.48 per share. | 25 Sep 2024 | 975 | 307,972 | - | 45.5 | 44,342 | Class A Common Stock |
| Vera Therapeutics Inc - Or... | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Sep 2024 | 975 | 308,947 | - | 2.9 | 2,824 | Class A Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges